The SLE project will parallel some aspects of the ACR’s previous efforts in RA. The 2012 update to the ACR’s RA treatment guidelines recommended that rheumatologists conduct regular RA disease activity assessments to support a treat-to-target strategy. Further, the ACR developed RISE registry quality measures that reinforced the importance of regularly assessing patient outcomes. These actions have improved understanding of the disease state and treatment responses of RA patients.
“The first piece of this project is developing the core data and assessment of tools. The next steps are to develop quality measures, then get practitioners involved and supported through implementation of improvement opportunities,” Dr. Bartels explains. “That’s what we’ve seen happen with RA over the last decade. Capturing disease activity and other data has become part of routine medical practice across the country, and we see better outcomes for patients because of it. That’s what we want to see for our patients with SLE.”
RISE users are advancing rheumatology while tracking their quality performance. Are you interested in joining RISE? Find more information on the RISE registry website or contact registry staff at [email protected].
